Healthcare / Diagnostics & ResearchLSE
$12.00
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-1.7M · quality 51.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
41/100
C
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$30M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-64.4%
↓Gross Margin
44.3%
↓Debt/Equity
0.19
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+43.8%
FCF CAGR
—
FCF margin
-41.9%
FCF / Net income
1.03x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $8.4M · net income $-3.4M · FCF $-3.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $8.4M | $8.4M | $6.1M | $4.0M | $2.8M |
| Net Income | $-3.4M | $-3.4M | $-1.3M | $-3.5M | $-21.3M |
| EBITDA | $-2.8M | $-2.8M | $-916000.00 | $-2.8M | $-19.9M |
| EPS | -0.01 | -0.01 | -0.00 | -0.01 | -0.07 |
| Gross Margin | 44.3% | 44.3% | 60.0% | 51.3% | -126.7% |
| Operating Margin | -41.6% | -41.6% | -22.4% | -89.3% | -423.7% |
| Net Margin | -40.5% | -40.5% | -20.7% | -85.8% | -750.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.19 | 0.19 | 0.47 | 0.34 | 0.20 |
| Current Ratio | 1.91 | 1.91 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-3.5M | $-3.5M | $-1.7M | $756000.00 | $-8.5M |
| Returns | |||||
| ROE | -64.4% | -64.4% | -56.5% | -116.7% | -331.5% |
| Valuation | |||||
| P/B | 844.97 | 844.97 | 1404.66 | 1157.63 | 454.74 |
| Growth & Yield | |||||
| Revenue Growth | 37.4% | 37.4% | 51.7% | 42.7% | — |
| EPS Growth | -121.4% | -121.4% | 63.2% | 84.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+71.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.00 → -0.01
Residual
+71.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.